Protective effects of SIRT1 in patients with proliferative diabetic retinopathy via the inhibition of IL-17 expression

Liu,Shulin; Lin,Yu; Liu,Xin

doi:10.3892/etm.2015.2877

Protective effects of SIRT1 in patients with proliferative diabetic retinopathy via the inhibition of IL-17 expression

Authors:
- Shulin Liu
- Yu Lin
- Xin Liu
View Affiliations

Affiliations: Chongqing Key Laboratory of Ophthalmology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China, Department of Traditional Chinese Medicine, Chongqing Medical University, Chongqing 400016, P.R. China, Department of Pharmacy, Chongqing Medical University, Chongqing 400016, P.R. China
Published online on: November 18, 2015 https://doi.org/10.3892/etm.2015.2877
Pages: 257-262

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Diabetic retinopathy (DR) is a chronic microvascular complication of diabetes that may lead to loss of vision. The pathogenesis of DR is complex and elevated expression levels of T helper (Th)17 cells and interleukin (IL)‑17 have been suggested to be associated with the development and progression of DR. Sirtuin 1 (SIRT1) is a nicotinamide‑adenine dinucleotide+‑dependent histone deacetylase that is downregulated in patients with DR. Previous studies have demonstrated that SIRT1 is capable of inhibiting the production of IL‑17. In the present study, 19 patients with proliferative diabetic retinopathy (PDR) and 20 non‑diabetic controls with idiopathic macular epiretinal membranes were recruited and the SIRT1 expression levels of excised specimens were analyzed using immunohistochemistry. IL‑17 expression levels in the sera from patients with PDR and controls were determined by enzyme‑linked immunosorbent assay (ELISA). Furthermore, SIRT1 mRNA and protein expression levels in peripheral blood mononuclear cells (PBMCs) from the two groups were analyzed following culture with or without a SIRT1 activator, resveratrol. IL‑17 expression levels in the supernatants of PBMCs were determined using ELISA and the results demonstrated that IL‑17 expression levels were increased in the sera of patients with PDR, as compared with the controls. Furthermore, increased expression levels of SIRT1 and IL‑17 were detected in fibrovascular membranes and PBMCs harvested from patients with PDR, respectively. Notably, SIRT1 mRNA and protein expression levels were decreased in the PBMCs of patients with PDR and IL‑17 production was inhibited following SIRT1 activation. The results of the present study indicated that imbalanced IL‑17 and SIRT1 expression levels may contribute to the pathogenesis of DR, and SIRT1 may have a protective role in PDR by inhibiting the production of IL-17.

View Figures

View References

1	Hendrick AM, Gibson MV and Kulshreshtha A: Diabetic retinopathy. Prim Care. 42:451–464. 2015. View Article : Google Scholar : PubMed/NCBI
2	Zhang X, Bao S, Lai D, Rapkins RW and Gillies MC: Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas. Diabetes. 57:1026–1033. 2008. View Article : Google Scholar : PubMed/NCBI
3	Frank RN: Diabetic retinopathy. N Engl J Med. 350:48–58. 2004. View Article : Google Scholar : PubMed/NCBI
4	Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, Chen SJ, Dekker JM, Fletcher A, Grauslund J, et al: Meta-Analysis for Eye Disease (META-EYE) Study Group: Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 35:556–564. 2012. View Article : Google Scholar : PubMed/NCBI
5	Cheung CM, Vania M, Ang M, Chee SP and Li J: Comparison of aqueous humor cytokine and chemokine levels in diabetic patients with and without retinopathy. Mol Vis. 18:830–837. 2012.PubMed/NCBI
6	Giacco F and Brownlee M: Oxidative stress and diabetic complications. Circ Res. 107:1058–1070. 2010. View Article : Google Scholar : PubMed/NCBI
7	Milne R and Brownstein S: Advanced glycation end products and diabetic retinopathy. Amino Acids. 44:1397–1407. 2013. View Article : Google Scholar : PubMed/NCBI
8	Xu H, Cai M and Zhang X: Effect of the blockade of the IL-23-Th17-IL-17A pathway on streptozotocin-induced diabetic retinopathy in rats. Graefes Arch Clin Exp Ophthalmol. 253:1485–1492. 2015. View Article : Google Scholar : PubMed/NCBI
9	Afzal N, Zaman S, Asghar A, Javed K, Shahzad F, Zafar A and Nagi AH: Negative association of serum IL-6 and IL-17 with type-II diabetes retinopathy. Iran J Immunol. 11:40–48. 2014.PubMed/NCBI
10	Takeuchi M, Sato T, Tanaka A, Muraoka T, Taguchi M, Sakurai Y, Karasawa Y and Ito M: Elevated levels of cytokins associated with Th2 and Th17 cells in vitreous fluid of proliferative diabetic retinopathy patients. PLoS One. 10:e01373582015. View Article : Google Scholar : PubMed/NCBI
11	Nadeem A, Javaid K, Sami W, Zafar A, Jahan S, Zaman S and Nagi A: Inverse relationship of serum IL-17 with type-II diabetes retinopathy. Clin Lab. 59:1311–1317. 2013.PubMed/NCBI
12	Afzal N, Zaman S, Shahzad F, Javaid K, Zafar A and Nagi AH: Immune mechanisms in type-2 diabetic retinopathy. J Pak Med Assoc. 65:159–163. 2015.PubMed/NCBI
13	Longo VD and Kennedy BK: Sirtuins in aging and age-related disease. Cell. 126:257–268. 2006. View Article : Google Scholar : PubMed/NCBI
14	Li T, Zhang J, Feng J, Li Q, Wu L, Ye Q, Sun J, Lin Y, Zhang M, Huang R, et al: Resveratrol reduces acute lung injury in a LPS-induced sepsis mouse model via activation of Sirt1. Mol Med Rep. 7:1889–1895. 2013.PubMed/NCBI
15	Sung B, Chung JW, Bae HR, Choi JS, Kim CM and Kim ND: Humulus japonicus extract exhibits antioxidative and anti-aging effects via modulation of the AMPK-SIRT1 pathway. Exp Ther Med. 9:1819–1826. 2015.PubMed/NCBI
16	Balaiya S, Khetpal V and Chalam KV: Hypoxia initiates sirtuin1-mediated vascular endothelial growth factor activation in choroidal endothelial cells through hypoxia inducible factor-2α. Mol Vis. 18:114–120. 2012.PubMed/NCBI
17	Zheng Z, Chen H, Li J, Li T, Zheng B, Zheng Y, Jin H, He Y, Gu Q and Xu X: Sirtuin 1-mediated cellular metabolic memory of high glucose via the LKB1/AMPK/ROS pathway and therapeutic effects of metformin. Diabetes. 61:217–228. 2012. View Article : Google Scholar : PubMed/NCBI
18	Gardner PJ, Joshi L, Lee RW, Dick AD, Adamson P and Calder VL: SIRT1 activation protects against autoimmune T cell-driven retinal disease in mice via inhibition of IL-2/Stat5 signaling. J Autoimmun. 42:117–129. 2013. View Article : Google Scholar : PubMed/NCBI
19	Park YD, Kim YS, Jung YM, Lee SI, Lee YM, Bang JB and Kim EC: Porphyromonas gingivalis lipopolysaccharide regulates interleukin (IL)-17 and IL-23 expression via SIRT1 modulation in human periodontal ligament cells. Cytokine. 60:284–293. 2012. View Article : Google Scholar : PubMed/NCBI
20	Alberti KG and Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic Med. 15:539–553. 1998. View Article : Google Scholar : PubMed/NCBI
21	Remmele W and Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Der Pathologe. 8:138–140. 1987.(In German). PubMed/NCBI
22	Wang C, Tian Y, Ye Z, Kijlstra A, Zhou Y and Yang P: Decreased interleukin 27 expression is associated with active uveitis in Behçet's disease. Arthritis Res Ther. 16:R1172014. View Article : Google Scholar : PubMed/NCBI
23	Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, et al: Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 425:191–196. 2003. View Article : Google Scholar : PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q and Dong C: A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 6:1133–1141. 2005. View Article : Google Scholar : PubMed/NCBI
26	Sumarac-Dumanovic M, Jeremic D, Pantovic A, Janjetovic K, Stamenkovic-Pejkovic D, Cvijovic G, Stevanovic D, Micic D and Trajkovic V: Therapeutic improvement of glucoregulation in newly diagnosed type 2 diabetes patients is associated with a reduction of IL-17 levels. Immunobiology. 218:1113–1118. 2013. View Article : Google Scholar : PubMed/NCBI
27	Zizzo G, De Santis M, Bosello SL, Fedele AL, Peluso G, Gremese E, Tolusso B and Ferraccioli G: Synovial fluid-derived T helper 17 cells correlate with inflammatory activity in arthritis, irrespectively of diagnosis. Clin Immunol. 138:107–116. 2011. View Article : Google Scholar : PubMed/NCBI
28	Lynde CW, Poulin Y, Vender R, Bourcier M and Khalil S: Interleukin 17A: Toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol. 71:141–150. 2014. View Article : Google Scholar : PubMed/NCBI
29	Esendagli G, Kurne AT, Sayat G, Kilic AK, Guc D and Karabudak R: Evaluation of Th17-related cytokines and receptors in multiple sclerosis patients under interferon β-1 therapy. J Neuroimmunol. 255:81–84. 2013. View Article : Google Scholar : PubMed/NCBI
30	Wong CK, Lit LC, Tam LS, Li EK, Wong PT and Lam CW: Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: Implications for Th17-mediated inflammation in auto-immunity. Clin Immunol. 127:385–393. 2008. View Article : Google Scholar : PubMed/NCBI
31	Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T, Robbins PD, Tahara H and Lotze MT: Interleukin-17 promotes angiogenesis and tumor growth. Blood. 101:2620–2627. 2003. View Article : Google Scholar : PubMed/NCBI
32	Suryawanshi A, Veiga-Parga T, Reddy PB, Rajasagi NK and Rouse BT: IL-17A differentially regulates corneal vascular endothelial growth factor (VEGF)-A and soluble VEGF receptor 1 expression and promotes corneal angiogenesis after herpes simplex virus infection. J Immunol. 188:3434–3446. 2012. View Article : Google Scholar : PubMed/NCBI
33	Chen Y, Yang P, Li F and Kijlstra A: The effects of Th17 cytokines on the inflammatory mediator production and barrier function of ARPE-19 cells. PLoS One. 6:e181392011. View Article : Google Scholar : PubMed/NCBI
34	Lee SI, Min KS, Bae WJ, Lee YM, Lee SY, Lee ES and Kim EC: Role of SIRT1 in heat stress- and lipopolysaccharide-induced immune and defense gene expression in human dental pulp cells. J Endod. 37:1525–1530. 2011. View Article : Google Scholar : PubMed/NCBI
35	Kim YS, Lee YM, Park JS, Lee SK and Kim EC: SIRT1 modulates high-mobility group box 1-induced osteoclastogenic cytokines in human periodontal ligament cells. J Cell Biochem. 111:1310–1320. 2010. View Article : Google Scholar : PubMed/NCBI
36	Beier UH, Wang L, Bhatti TR, Liu Y, Han R, Ge G and Hancock WW: Sirtuin-1 targeting promotes Foxp3⁺ T-regulatory cell function and prolongs allograft survival. Mol Cell Biol. 31:1022–1029. 2011. View Article : Google Scholar : PubMed/NCBI
37	Maloney SC, Antecka E, Granner T, Fernandes B, Lim LA, Orellana ME and Burnier MN Jr: Expression of SIRT1 in choroidal neovascular membranes. Retina. 33:862–866. 2013. View Article : Google Scholar : PubMed/NCBI
38	Pacholec M, Bleasdale JE, Chrunyk B, Cunningham D, Flynn D, Garofalo RS, Griffith D, Griffor M, Loulakis P and Pabst B: SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem. 285:8340–8351. 2010. View Article : Google Scholar : PubMed/NCBI